VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 1,689,232 shares, an increase of 250.0% from the December 15th total of 482,674 shares. Based on an average daily trading volume, of 25,987,592 shares, the days-to-cover ratio is presently 0.1 days. Approximately 5.2% of the company’s shares are short sold. Approximately 5.2% of the company’s shares are short sold. Based on an average daily trading volume, of 25,987,592 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On VYNE Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP acquired a new stake in VYNE Therapeutics in the 3rd quarter valued at approximately $285,000. Adage Capital Partners GP L.L.C. raised its holdings in shares of VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after buying an additional 300,000 shares during the period. Kennedy Capital Management LLC acquired a new position in VYNE Therapeutics during the 2nd quarter worth about $942,000. Shay Capital LLC acquired a new position in VYNE Therapeutics during the 3rd quarter worth about $165,000. Finally, Patient Square Capital LP boosted its holdings in VYNE Therapeutics by 23.3% during the 2nd quarter. Patient Square Capital LP now owns 317,033 shares of the company’s stock valued at $523,000 after acquiring an additional 60,000 shares during the period. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Stock Down 1.7%

NASDAQ:VYNE opened at $0.56 on Tuesday. VYNE Therapeutics has a 52 week low of $0.28 and a 52 week high of $3.40. The stock’s fifty day moving average is $0.45 and its two-hundred day moving average is $0.55. The company has a market capitalization of $18.64 million, a P/E ratio of -0.72 and a beta of 1.95.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%.The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.13 million. Sell-side analysts anticipate that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on VYNE. Wall Street Zen upgraded VYNE Therapeutics to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $4.50.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.